COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Alpharadin™ (Radium-223 Chloride) Safety and Dosimetry With HRPC That Has Metastasized to the Skeleton

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00748046
Recruitment Status : Completed
First Posted : September 8, 2008
Last Update Posted : June 25, 2014
Information provided by (Responsible Party):

Brief Summary:
The purpose of the study is to investigate the safety, biodistribution, radiation dosimetry and pharmacokinetics of three intravenous escalating dose levels of Xofigo (Alpharadin).

Condition or disease Intervention/treatment Phase
Prostate Cancer Metastases Pharmacokinetics Drug: Radium-223 chloride (BAY88-8223) Phase 1

Detailed Description:
Within the U.S., the trial is conducted under an IND sponsored by Bayer.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 10 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Basic Science
Official Title: Phase 1, Open-label, Single Ascending-dose Study to Assess Safety, Pharmacokinetics, Biodistribution and Radiation Dosimetry of Intravenous Doses of Alpharadin™ Injection (Radium-223 Chloride) in Patients With HRPC and Skeletal Metastases
Study Start Date : August 2008
Actual Primary Completion Date : October 2009
Actual Study Completion Date : October 2009

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: Radium-223 chloride (Xofigo, BAY88-8223)
The patients will receive Radium-223 chloride as an escalating dose of either 50, 100 or 200 kBq/kg b.w. (0.0014, 0.0027 or 0.0054 mCi/kg).
Drug: Radium-223 chloride (BAY88-8223)
The required volume of study drug to be administered to a patient was calculated using the patient's body weight.

Primary Outcome Measures :
  1. All safety data, including adverse events, occurrence of treatment-emergent adverse events, changes in laboratory variables, vital signs, ECG, physical examination, long term radiation toxicity, including results of bone marrow biopsy [ Time Frame: 1 year ]
  2. Biodistribution, dosimetry and pharmacokinetics (whole body activity assessment, the counts in region-of-interest (ROIs) from anterior and posterior whole-body images, and the assay of activity in blood [ Time Frame: 6 days after injection ]

Secondary Outcome Measures :
  1. Post-treatment PSA effect: PSA decline, time to PSA progression after PSA response [ Time Frame: 1 year ]
  2. Post-treatment bone markers effect: Changes in bone marker values from pre- to post administration [ Time Frame: 1 year ]
  3. Circulating tumor cells (CTCs) enumeration and role of molecular profiling of CTC in predicting sensitivity to treatment and treatment response [ Time Frame: 1 year ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Must be ≥18 years of age
  • Have histologically or cytologically evidence of adenocarcinoma of the prostate
  • Have progressive castrate metastatic disease as shown by at least one of the following:

    • Imaging modalities:

      • Radionuclide Bone Scan: New osseous lesions
      • MRI or CT: At least a 20% increase in the sum of the LD of target lesions OR
    • Biochemical progression: A minimum of three rising PSA values from a baseline that are obtained 1 week or more apart, or 2 measurements 2 or more weeks apart
  • Have skeletal metastases confirmed by bone scintigraphy within the last 4 weeks. Evidence of at least 2 bone metastases on bone scan.
  • Have castrate levels of testosterone (<50 ng/ml). Treatment to maintain castrate levels of testosterone must be continued.
  • Patients who have failed initial hormonal therapy using either an orchiectomy or a GnRH agonist in combination with an antiandrogen must first progress through antiandrogen withdrawal prior to being eligible. The minimum timeframe to document failure of anti-androgen withdrawal will be four weeks.
  • Have Karnofsky performance status ≥60%
  • Have a life expectancy ≥6 months
  • Have the following laboratory requirements:

    • White Blood Count (WBC) ≥3,000/mm3
    • Absolute Neutrophil Count (ANC) ≥1,500/ mm3
    • Platelet (PLT) ≥100,000/ mm3
    • Hemoglobin (HGB) ≥10 mg/dl
    • Bilirubin ≤2.0 mg/dl (unless the patient has Gilbert's syndrome)
    • AST and ALT ≤2,5 times upper institutional limit of the normal range
    • Serum creatinine ≤2.0 mg/dl
  • Must be able and willing to sign an informed consent indicating that he is aware of the investigational nature of this study in keeping with the policies of the institution and have provided written authorization for use and disclosure of protected health information
  • Must be willing and able to comply with the protocol, and agrees to return to the hospital for follow-up visits and examination

Exclusion Criteria:

  • Have received an investigational drug within 4 weeks prior to the administration of Radium-223 chloride, or is scheduled to receive one during the treatment and post-treatment period
  • Have received chemo-, immunotherapy, or external radiotherapy within the last 4 weeks prior to administration of study drug, or has not recovered from acute adverse events as a result of such therapy
  • Have received prior hemibody external radiotherapy
  • Have a need for immediate external radiotherapy
  • Have received systemic radiotherapy with radium-223, strontium-89, samarium-153, rhenium-186 or rhenium-188 for the treatment of bony metastases within the last 24 weeks prior to administration of study drug
  • When receiving bisphosphonates, have changed the dose within 4 weeks before administration of study drug
  • Have started or stopped systemic steroids within a week prior to study drug administration, or are expected to be subject to changes in the systemic steroid medication
  • Have imminent or established spinal cord compression based on clinical findings and/or MRI
  • Have other currently active (relapse within the last 3 years) malignancy (except non-melanoma skin cancer) that are not prostate cancer metastases
  • Have small cell carcinoma
  • Have predominant visceral metastases (≥ 3 lung or liver lesions) or symptomatic lymph-adenopathy (scrotal or pedal edema)
  • Any other serious illness or medical condition, for example:

    • any uncontrolled infection
    • any patient who has clinical heart failure severe enough to cause marked limitation of activity, and who is only comfortable at rest; or any patient who has heart failure more severe than this (NYHA Heart Failure Class III or IV)
    • Crohn's disease or ulcerative colitis

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00748046

Layout table for location information
United States, New York
New York, New York, United States, 10065
Sponsors and Collaborators
Layout table for investigator information
Principal Investigator: Michael J. Morris, MD Memorial Sloan Kettering Cancer Center
Publications of Results:
Layout table for additonal information
Responsible Party: Bayer Identifier: NCT00748046    
Other Study ID Numbers: 15303
BC1-08 ( Other Identifier: Algeta ASA )
First Posted: September 8, 2008    Key Record Dates
Last Update Posted: June 25, 2014
Last Verified: June 2014
Keywords provided by Bayer:
Radiation dosimetry
Additional relevant MeSH terms:
Layout table for MeSH terms
Neoplasm Metastasis
Neoplastic Processes
Pathologic Processes
Radium Ra 223 dichloride
Antineoplastic Agents